Suppression of angiogenesis is an important component of the anti-cancer activity of Bortezomib, and is thought to largely occur via inhibition of NF-κB - which induces the expression of many proangiogenic factors, including vascular endothelial growth factor (VEGF). Here, NFKB1 is linked to cancer.